X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PRV-002 (ONP-002) is a first-in-class neurosteroid, which is being evaluated in phase 1 clinical trials for the treatment of mild traumatic brain injury.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
The Company intends to use the net proceeds from the offering to fund the continued development of ONP-002, a fully synthetic, non-naturally occurring neurosteroid, for the treatment of moderate to severe concussions.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ONP-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering March 01, 2024
Details:
The company intends to use the net proceeds from the offering to fund the continued development of ONP-002, a unique neurosteroid drug compound intended to treat mild traumatic brain injuries also known as concussions.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ONP-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 27, 2024
Details:
PRV-002 (ONP-002) is a first-in-class neurosteroid, which is being evaluated in phase 1 clinical trials for the treatment of mild traumatic brain injury.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
Through the acquisition, Oragenics gain Odyssey’s assets including drug candidates, ONP-002 for treating mild traumatic brain injury, and for treating Niemann Pick Disease Type C, as well as Odyssey’s proprietary powder formulation and its nasal delivery device.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ONP-002
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Odyssey Health
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 02, 2024
Details:
Through the agreement, Oragenics acquire Odyssey’s assets including drug candidates, ONP-002 for treating mild traumatic brain injury, and for treating Niemann Pick Disease Type C, as well as Odyssey’s proprietary powder formulation and its nasal delivery device.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ONP-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Odyssey Health
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 05, 2023
Details:
The funding will be used to develop a variant-agnostic protein antigen for use in its lead product, NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.
Lead Product(s): NT-CoV2-1
Therapeutic Area: Infections and Infectious Diseases Product Name: NT-CoV2-1
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: CQDM
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 05, 2023
Details:
Lantibiotics platform is focused on the development of new antibiotics effective against certain pathogens including vancomycin-resistant Enterococci (VRE) and methicillinresistant Staphylococcus aureus (MRSA).
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Under the exclusive licensing agreement, Oragenics will pursue the development of its lead intranasal COVID-19 vaccine candidate, NT-CoV2-1 (SmT1v3) with Inspirevax’s novel BDX301 intranasal mucosal adjuvant.
Lead Product(s): SmT1v3,BDX301
Therapeutic Area: Infections and Infectious Diseases Product Name: NT-CoV2-1
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Inspirevax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 01, 2023
Details:
Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Lead Product(s): NT-CoV2-1
Therapeutic Area: Infections and Infectious Diseases Product Name: NT-CoV2-1
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
